Left Atrial Volume Changes Who Underwent Cardioversion and Recurrence of AF After RF Ablation in Persistent AF (SAFE-AF)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe Second Affiliated Hospital of Chongqing Medical University

About this trial

Electrical/pharmacological cardioversion improves structural remodeling of left atrium. We hypothesize that persistent atrial fibrillation (AF) patients with more significant left atrial size reduction after cardioversion have lower AF recurrence rates following radiofrequency ablation. The aim is to evaluate the relationship between changes in left atrial size 3 to 6 months after cardioversion and the recurrence rate of atrial fibrillation following radiofrequency ablation.

Eligibility criteria

Qualifiers

Patients with estabolished diagnosis of Persistent Atrial Fibrillation during past 6 mnths.

LAD brfore entering the two cohorts is more than 40mm, and less than 50mm.

Pharmacological or electrical cardioversion has be performed successfully.

At least two echocardiograms were performed before and 3-6 months after cardioversion., and confirm the status of LAD (Reversal, unchange, enlargment).

Disqualifiers

Prior radiofrequency ablation treatment for atrial fibrillation

Prior cardiac surgical procedures

Individuals with cognitive impairments who are unable to give informed consent

Trial design

Treatments tested in this trial

  • 1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation

Treatment groups

100 Participants
are divided into 2 treatment groups